This Article Full Text Full Text (PDF) All Versions of this Article: 39/5/1448    most recent STROKEAHA.107.503193v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mannheim, D. Articles by Lerman, A. Search for Related Content PubMed PubMed Citation Articles by Mannheim, D. Articles by Lerman, A. Related Collections Pathophysiology Brain Circulation and Metabolism Other Vascular biology

(Stroke. 2008;39:1448.)
© 2008 American Heart Association, Inc.

Original Contributions

Enhanced Expression of Lp-PLA₂ and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques

Dallit Mannheim, MD; Joerg Herrmann, MD; Daniele Versari, MD; Mario Gössl, MD; Fredric B. Meyer, MD; Joseph P. McConnell, PhD; Lilach O. Lerman, MD, PhD Amir Lerman, MD

From the Divisions of Cardiovascular Diseases (D.M., J.H., D.V., M.G., L.O.L., A.L.), Neurosurgery (F.B.M.), Cardiovascular-Laboratory Medicine and Immunochemical Core Laboratory (J.P.M.), and Nephrology and Hypertension (L.O.L.), Mayo Clinic College of Medicine, Rochester, Minn.

Correspondence to Amir Lerman, MD, Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN, 55905. E-mail lerman.amir{at}mayo.edu

Background and Purpose— Circulating lipoprotein-associated phospholipase A₂ (Lp-PLA₂) has emerged as a novel biomarker for cardiovascular diseases. However, the correlation between the plaque expression of Lp-PLA₂ and plaque oxidative stress, inflammation, and stability as well as the clinical presentation remains poorly defined, especially for cerebrovascular disease. Therefore, this study was performed to test the hypothesis that Lp-PLA₂ expression is higher in symptomatic than in asymptomatic carotid plaques of patients undergoing carotid endarterectomy.

Methods— The expression of Lp-PLA₂ in 167 carotid artery plaques was determined by immunoblotting and immunostaining. Plaque oxidative stress, inflammation, and stability were quantified by NAD(P)H oxidase p67phox and MMP-2 immunoblotting, oxidized LDL (oxLDL) immunoreactivity, macrophage and Sirius red collagen staining. Lysophosphatidylcholine 16:0 (lysoPC) concentration was measured in 55 plaques using liquid chromatography tandem mass spectrometry.

Results— Lp-PLA₂ expression was significantly higher in plaques of symptomatic patients than asymptomatic patients (1.66±0.19 versus 1.14±0.10, P<0.05) and localized mainly to shoulder and necrotic lipid core areas in colocalization with oxLDL and macrophage content. Similarly, Lp-PLA₂ expression was related to collagen content, which was lower in plaques from symptomatic patients than in plaques from asymptomatic patients (9.1±2.2 versus 18.5±1.7% of staining/field, P<0.001). LysoPC plaque concentration was significantly higher in plaques of symptomatic than asymptomatic patients (437.0±57.91 versus 228.84±37.00 mmol/L, P<0.05).

Conclusions— Symptomatic carotid artery plaques are characterized by increased levels of Lp-PLA₂ and its product lysoPC in correlation with markers of tissue oxidative stress, inflammation, and instability. These findings strongly support a role for Lp-PLA2 in the pathophysiology and clinical presentation of cerebrovascular disease.

Key Words: Lp-PLA_2, lysophosphatidylcholine • carotid • atherosclerosis • unstable plaque

This article has been cited by other articles:

				K. C. Vickers, C. T. Maguire, R. Wolfert, A. R. Burns, M. Reardon, R. Geis, P. Holvoet, and J. D. Morrisett Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis J. Lipid Res., September 1, 2009; 50(9): 1735 - 1743. [Abstract] [Full Text] [PDF]

				T. Munzel and T. Gori Lipoprotein-associated phospholipase A2, a marker of vascular inflammation and systemic vulnerability Eur. Heart J., August 30, 2009; (2009) ehp311v1. [Full Text] [PDF]

				J. Herrmann, D. Mannheim, C. Wohlert, D. Versari, F. B. Meyer, J. P. McConnell, M. Gossl, L. O. Lerman, and A. Lerman Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome Eur. Heart J., August 17, 2009; (2009) ehp309v1. [Abstract] [Full Text] [PDF]

				B. L. Cucchiara, S. R. Messe, L. Sansing, L. MacKenzie, R. A. Taylor, J. Pacelli, Q. Shah, and S. E. Kasner Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Risk-Stratification of Patients With TIA Stroke, July 1, 2009; 40(7): 2332 - 2336. [Abstract] [Full Text] [PDF]

				S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu, and S. Kiechl Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study Eur. Heart J., January 1, 2009; 30(1): 107 - 115. [Abstract] [Full Text] [PDF]

				U. Samanta and B. J. Bahnson Crystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase: STRUCTURAL IMPLICATION TO LIPOPROTEIN BINDING AND CATALYSIS J. Biol. Chem., November 14, 2008; 283(46): 31617 - 31624. [Abstract] [Full Text] [PDF]